List of bibliographic references
Number of relevant bibliographic references: 1.
List of associated KwdEn.i
Nombre de documents | Descripteur |
1 | Androstadienes (administration & dosage) |
1 | Antibodies, Monoclonal, Humanized (administration & dosage) |
1 | Antineoplastic Agents, Hormonal (therapeutic use) |
1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
1 | Aromatase Inhibitors (administration & dosage) |
1 | Bevacizumab |
1 | Biomarkers, Tumor (analysis) |
1 | Breast Neoplasms (chemistry) |
1 | Breast Neoplasms (drug therapy) |
1 | Breast Neoplasms (mortality) |
1 | Clinical Trials as Topic |
1 | Disease-Free Survival |
1 | Estradiol (administration & dosage) |
1 | Estradiol (analogs & derivatives) |
1 | Everolimus |
1 | Female |
1 | Humans |
1 | Molecular Targeted Therapy (methods) |
1 | Nitriles (administration & dosage) |
1 | Patient Selection |
1 | Postmenopause |
1 | Receptor, ErbB-2 (analysis) |
1 | Receptor, ErbB-2 (antagonists & inhibitors) |
1 | Receptors, Estrogen (analysis) |
1 | Receptors, Estrogen (antagonists & inhibitors) |
1 | Receptors, Progesterone (analysis) |
1 | Receptors, Progesterone (antagonists & inhibitors) |
1 | Sirolimus (administration & dosage) |
1 | Sirolimus (analogs & derivatives) |
1 | Treatment Failure |
1 | Treatment Outcome |
1 | Triazoles (administration & dosage) |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Carlos Barrios"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Carlos Barrios" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Carlos Barrios
}}
| This area was generated with Dilib version V0.6.33. Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 | |